Profile data is unavailable for this security.
About the company
Abivax SA is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
- Revenue in EUR (TTM)0.00
- Net income in EUR-177.43m
- Incorporated2013
- Employees62.00
- LocationAbivax SA7-11 Boulevard HaussmannPARIS 75009FranceFRA
- Phone+33 153830963
- Fax+33 494279261
- Websitehttps://www.abivax.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cellectis SA | 33.93m | -98.20m | 126.68m | 235.00 | -- | 1.04 | -- | 3.73 | -1.38 | -1.09 | 0.3939 | 1.69 | 0.119 | -- | 6.23 | 144,371.00 | -35.11 | -24.08 | -53.69 | -30.69 | -- | -64.64 | -294.96 | -308.24 | -- | -2.77 | 0.452 | -- | -64.26 | -15.57 | -20.55 | -- | -26.15 | -- |
| Adocia SA | 523.00k | -20.72m | 134.91m | 79.00 | -- | -- | -- | 257.96 | -1.53 | -1.53 | 0.0382 | -0.5123 | 0.0234 | 1.15 | 3.15 | 6,705.13 | -92.78 | -43.08 | -- | -72.93 | 32.50 | -- | -3,960.99 | -514.53 | 0.8927 | -2.79 | 2.38 | -- | -81.22 | -46.13 | -206.65 | -- | -27.60 | -- |
| Innate Pharma SA | 24.85m | -34.05m | 136.35m | 168.00 | -- | 4.73 | -- | 5.49 | -0.4215 | -0.4215 | 0.3078 | 0.3557 | 0.1418 | -- | 14.93 | 138,826.80 | -19.43 | -8.83 | -24.80 | -12.11 | 88.00 | 93.17 | -137.03 | -55.55 | -- | -- | 0.7527 | -- | 4.68 | -8.27 | 86.94 | -- | 10.50 | -- |
| Nanobiotix SA | 36.22m | -33.47m | 178.64m | 102.00 | -- | -- | -- | 4.93 | -0.763 | -0.763 | 0.8429 | -0.4594 | 0.57 | -- | 17.20 | 355,107.80 | -52.68 | -54.11 | -323.15 | -80.68 | -- | -- | -92.42 | -756.15 | -- | -2.42 | 1.87 | -- | -- | 203.88 | 30.40 | -- | -7.81 | -- |
| Ose Immunotherapeutics SA | 83.44m | 46.03m | 203.78m | 52.00 | 4.11 | 2.50 | 4.13 | 2.44 | 2.27 | 2.27 | 4.10 | 3.74 | 0.7541 | -- | 32.09 | 1,517,127.00 | 41.60 | -17.17 | 49.66 | -20.55 | -- | -- | 55.17 | -94.71 | -- | 9.24 | 0.3502 | -- | -87.83 | -38.07 | -29.52 | -- | -17.11 | -- |
| Sensorion SA | 0.00 | -23.67m | 212.15m | 61.00 | -- | 2.54 | -- | -- | -0.1048 | -0.1048 | 0.00 | 0.2777 | 0.00 | -- | -- | 0.00 | -36.68 | -35.12 | -47.21 | -46.97 | -- | -- | -- | -- | -- | -- | 0.0274 | -- | -- | -- | 4.94 | -- | 126.45 | -- |
| Inventiva SA | 15.62m | -104.19m | 213.34m | 123.00 | -- | -- | -- | 13.66 | -2.08 | -2.08 | 0.3104 | -1.51 | 0.2833 | -- | 10.30 | 139,437.50 | -185.05 | -54.30 | -839.50 | -69.98 | -- | -- | -653.15 | -669.97 | 0.586 | -12.21 | -- | -- | 43.50 | 40.46 | -103.46 | -- | -0.33 | -- |
| Genfit SA | 84.00m | 22.27m | 241.03m | 169.00 | 14.18 | 2.47 | 10.12 | 2.87 | 0.3404 | 0.3404 | 1.53 | 1.95 | 0.4322 | 543.50 | 2.61 | 528,308.20 | 11.46 | -12.57 | 14.53 | -15.30 | 97.41 | 94.96 | 26.51 | -76.23 | 3.74 | 9.33 | 0.4105 | -- | 43.70 | 38.49 | -21.82 | -- | -3.27 | -- |
| Eurobio Scientific SA | 144.25m | 6.64m | 263.91m | 137.00 | 40.99 | -- | 14.50 | 1.83 | 0.6282 | 0.6282 | 13.50 | -- | -- | -- | -- | 1,052,883.00 | -- | 16.91 | -- | 21.53 | 46.81 | 50.95 | 4.61 | 23.34 | -- | 5.62 | -- | 0.00 | -14.81 | 20.80 | -80.61 | -- | 20.02 | -- |
| Valneva SE | 158.54m | -7.42m | 363.99m | 695.00 | -- | 1.43 | 8.37 | 2.30 | -0.057 | -0.057 | 1.13 | 1.56 | 0.3057 | 2.03 | 4.24 | 231,777.80 | -1.43 | -15.39 | -2.09 | -25.06 | 38.58 | 35.94 | -4.68 | -34.95 | 2.25 | 2.06 | 0.4806 | -- | -57.46 | 6.34 | 29.21 | -- | 35.18 | -- |
| Abivax SA | 0.00 | -177.43m | 598.13m | 62.00 | -- | 4.70 | -- | -- | -3.20 | -3.20 | 0.00 | 2.01 | 0.00 | -- | -- | 0.00 | -77.89 | -65.49 | -107.73 | -97.67 | -- | -- | -- | -- | -- | -110.67 | 0.4334 | -- | -- | -- | -111.52 | -- | -19.06 | -- |
Data as of Nov 13 2024. Currency figures normalised to Abivax SA's reporting currency: Euro EUR
12.27%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Deep Track Capital LPas of 17 Jul 2024 | 3.13m | 4.94% |
| VHCP Management LLCas of 31 Dec 2023 | 2.61m | 4.13% |
| Pictet Asset Management SAas of 30 Jun 2024 | 718.59k | 1.14% |
| HBM Partners AG (Investment Management)as of 30 Jun 2024 | 717.00k | 1.13% |
| HSBC Global Asset Management (France) SAas of 30 Sep 2024 | 183.55k | 0.29% |
| Saint Olive Gestion SNCas of 29 Dec 2023 | 109.29k | 0.17% |
| CPR Asset Management SAas of 30 Aug 2024 | 103.08k | 0.16% |
| BlackRock Fund Advisorsas of 02 Oct 2024 | 67.54k | 0.11% |
| BlackRock Advisors (UK) Ltd.as of 03 Oct 2024 | 66.83k | 0.11% |
| Claresco Finance SAas of 30 Jun 2024 | 60.40k | 0.10% |
More ▼
Data from 31 Dec 2023 - 30 Sep 2024Source: FactSet Research Systems Inc.
